9987
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Suzuken Co., Ltd. is a Japanese pharmaceutical distribution and healthcare services company. The group operates through several business segments, including pharmaceutical wholesale, healthcare product development, regional medical and nursing care support, and specialty pharmaceutical logistics. Key subsidiaries include Sanki, Astis, Sho-Yaku, Suzuken Okinawa Yakuhin, Nakano Yakuhin, Suzuken Iwate, S.D. Logistics, Miwa Chemical Research Institute, Kents Medico, Unismile, Sanki Wellbee, S-Caremate, Medica Collaboration, S.D. Collaboration, Chuo Transport, and Collaboration Square. The company provides sales of medical drugs, diagnostic agents, medical devices, and materials, as well as research, development, and manufacturing of pharmaceuticals. It also offers insurance pharmacy services, nursing care, and logistics support for pharmaceutical manufacturers. The group serves the Japanese market, focusing on regional medical support and digital healthcare services.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Medical Distribution Homepage suzuken.co.jp
Sector Healthcare IR page suzuken.co.jp/ir
Tags
pharmaceutical distribution, medical devices, diagnostic agents, insurance pharmacy, nursing care, specialty pharmaceuticals, logistics, digital healthcare, pharmaceutical manufacturing, Sanki, Astis, Sho-Yaku, Suzuken Okinawa Yakuhin, Nakano Yakuhin, Suzuken Iwate, S.D. Logistics, Miwa Chemical Research Institute, Kents Medico, Unismile, Sanki Wellbee, S-Caremate, Medica Collaboration, S.D. Collaboration, Chuo Transport, Collaboration Square, Collaboration Create
Press page suzuken.co.jp/ir/news

Metrics

Valuation  
Market cap ¥ 184.532B
Market cap (USD) $ 1.153B
P/E 6.18
PEG 0.27
P/BV 0.44
P/S 0.07
P/OCF 8.11
P/FCF 22.26
Dividend yield 3.9%
Turnover / mcap —
Returns  
ROE 9.3%
ROI 9.2%
ROIC 6.1%
Profit margin 1.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 23.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score 44.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 2.487T 2.4T 2.386T 2.315T 2.233T 2.128T 2.213T 2.132T 2.124T 2.127T 2.228T 1.97T 1.988T 1.895T
Net profit 38.136B 34.496B 29.016B 20.345B 14.393B 7.895B 28.213B 30.204B 18.82B 21.308B 28.96B 18.92B 21.447B 14.35B
Free cash flow 15.718B -83.726B 71.576B 19.528B -4.772B 7.738B -34.087B 35.948B 90.12B 14.157B 8.154B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 5.943K 4.953K 4.651K 3.336K 3.627K 4.327K 3.937K 6.412K 4.397K 3.648K 3.831K 3.665K 3.636K 3.503K
Price performance 12m 0.2 0.06 0.39 -0.08 -0.16 0.1 -0.39 0.46 0.21 -0.05 0.05 0.01 0.04 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 498B 493B 501B 487B 491B 1.03T 1.04T 1.08T 1.05T 1.11T
↳ YoY growth -12.1% -0.9% +1.5% -2.8% +0.7% +110.9% +0.7% +3.6% -2.9% +5.7%
↳ 5y CAGR -2.8% +15.8% +16.1% +16.6% +16.6% +17.7%
Borrowings, current (JPY) 89M 145M 56M — — — — — — —
Borrowings, non-current (JPY) 15M 6M — — — — — — — —
Cash and deposits (JPY) 108B 195B 213B 168B 151B 141B 109B 182B 103B 117B
Intangible assets (JPY) 17.5B 15.2B 13.6B 11.1B 9.09B 11.2B 11B 11.2B 12.1B 15.7B
Net debt (borrowings + leases - cash) (JPY) -108B -195B -213B — — — — — — —
Cash flow detail
Operating cash flow (JPY) 27B 98.1B 41.8B -25.8B 15.6B 9.52B 37.3B 87.2B -65.1B 33.6B
Purchases of property, plant and equipment (JPY) -10.3B -5.5B -5.8B -8.27B -5.57B -11.2B -15.1B -10.8B -14.3B -15.1B
Purchases of intangible assets (JPY) -2.57B -2.44B -3.02B -3.43B -2.29B -3.14B -2.68B -4.83B -4.34B -2.78B
Change in receivables (cash effect) (JPY) 68.8B 4.78B -7.53B 13.9B -3.58B -25B -2.62B -19B 15.6B -30B
Change in inventories (cash effect) (JPY) 426M 8.21B -5.23B 6.39B 7.11B -5.18B -1.58B -3.09B -10.8B 641M
Change in payables (cash effect) (JPY) -59.9B 53.5B 24.2B -86.4B -392M 20B 2.23B 78.1B -108B 30B
Dividends paid (cash effect) (JPY) -6.84B -5.17B -6.06B -6.75B -6.78B -6.38B -6.33B -6.29B -6.99B -7.1B
Share buybacks (cash effect) (JPY) -9.83B -6.9B -20.5B -9.83B -1M -4.43B -19.5B -25B -28B -26B
Interest paid (cash effect) (JPY) -54M -58M -55M -53M -49M -51M -42M -43M -41M -42M
Income taxes paid (cash effect) (JPY) -16.9B -8.35B -13.1B -15.4B -9.93B -6.02B -10.2B -11.9B -13.6B -16.8B
Operating cash flow before change in receivables (JPY) -41.8B 93.3B 49.3B -39.7B 19.2B 34.5B 39.9B 106B -80.7B 63.6B
Free cash flow (OCF - PPE - intangibles) (JPY) 14.2B 90.1B 32.9B -37.5B 7.74B -4.77B 19.5B 71.6B -83.7B 15.7B
Income detail
Research and development expense (JPY) 7.64B 6.67B 5.87B 4.65B 3.45B 4.59B 2.95B 3.28B 3.52B 3.44B
↳ 5y CAGR -9.6% -9.7% -15.0% -11.0% -5.4% -0.1%
Total comprehensive income (JPY) 17.2B 22B 21.8B 27.6B 12B 11.2B 19.2B 36.2B 26.1B 41.4B
Comprehensive income to owners (JPY) 17.1B 21.9B 21.6B 27.5B 11.9B 11.1B 19.2B 36.2B 26.1B 41.4B
Provision for credit losses (JPY) 398M -369M -13M -24M -283M 165M 861M 418M 94M -619M
Credit cost ratio (credit losses / average receivables) (%) 0.1% 0.1% 0.0% 0.0% 0.1% 0.0% 0.1% 0.0% 0.0% 0.1%
Segments
The Community Healthcare And Nursing Care Support Business · Segment revenue (JPY) — — — — — — 98B 97.5B 94.4B 93.9B
↳ YoY growth -0.5% -3.1% -0.5%
The Community Healthcare And Nursing Care Support Business · Segment operating income (JPY) — — — — — — 2.59B 1.69B 1.29B 1.55B
The Healthcare Product Development Business · Segment revenue (JPY) — — — — — — 47.4B 51.3B 52.6B 51.6B
↳ YoY growth +8.1% +2.6% -1.9%
The Healthcare Product Development Business · Segment operating income (JPY) — — — — — — 1.56B 1.6B 1.92B 830M
The Specialty Drug Contract Distribution Business · Segment revenue (JPY) — — — — — — — 216B 295B 436B
↳ YoY growth +36.7% +47.6%
The Specialty Drug Contract Distribution Business · Segment operating income (JPY) — — — — — — — 569M 845M 1.16B
Reported Jun 28, 2017 Jun 27, 2018 Jun 26, 2019 Jun 25, 2020 Jun 25, 2021 Jun 24, 2022 Jun 25, 2024 Jun 25, 2025 Jun 25, 2025 Jun 22, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Suzuken Co., Ltd. (ticker 9987), listed in Japan.

ETFs Holding Suzuken Co., Ltd.

ETF Weight in ETF Shares Market value As of
DISV 0.16% 457,136 $ 8.135M Nov 12, 2026
AVDV 0.13% 1,427,100 $ 26.006M Nov 16, 2026
AVDS 0.08% 16,600 $ 302.502K Nov 16, 2026
DFIS 0.06% 195,200 $ 3.474M Nov 12, 2026
AVSD 0.04% 8,100 $ 147.607K Nov 16, 2026
DXIV 0.03% 4,200 $ 74.741K Nov 12, 2026
DFIC 0.02% 204,200 $ 3.634M Nov 12, 2026
DFSI 0.02% 15,600 $ 277.61K Nov 12, 2026
DFIV 0.02% 203,200 $ 3.616M Nov 12, 2026
DFAX 0.02% 107,120 $ 1.906M Nov 12, 2026
DFAI 0.01% 83,764 $ 1.491M Nov 12, 2026
AVDE 0.00% 46,200 $ 841.904K Nov 16, 2026